JP6165748B2 - 脱ユビキチン活性の阻害方法 - Google Patents
脱ユビキチン活性の阻害方法 Download PDFInfo
- Publication number
- JP6165748B2 JP6165748B2 JP2014537023A JP2014537023A JP6165748B2 JP 6165748 B2 JP6165748 B2 JP 6165748B2 JP 2014537023 A JP2014537023 A JP 2014537023A JP 2014537023 A JP2014537023 A JP 2014537023A JP 6165748 B2 JP6165748 B2 JP 6165748B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- compound
- compounds
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1100776 | 2011-10-19 | ||
| SE1100776-2 | 2011-10-19 | ||
| SE1200303-4 | 2012-05-16 | ||
| SE1200303 | 2012-05-16 | ||
| PCT/SE2012/000158 WO2013058691A1 (en) | 2011-10-19 | 2012-10-15 | Method for inhibition of deubiquitinating activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530852A JP2014530852A (ja) | 2014-11-20 |
| JP2014530852A5 JP2014530852A5 (OSRAM) | 2015-11-26 |
| JP6165748B2 true JP6165748B2 (ja) | 2017-07-19 |
Family
ID=48141165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537023A Expired - Fee Related JP6165748B2 (ja) | 2011-10-19 | 2012-10-15 | 脱ユビキチン活性の阻害方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9221761B2 (OSRAM) |
| EP (1) | EP2780326B1 (OSRAM) |
| JP (1) | JP6165748B2 (OSRAM) |
| KR (1) | KR102022575B1 (OSRAM) |
| CN (1) | CN104271557B (OSRAM) |
| AU (1) | AU2012326682B2 (OSRAM) |
| BR (1) | BR112014009365B1 (OSRAM) |
| CA (1) | CA2852518C (OSRAM) |
| CL (1) | CL2014000998A1 (OSRAM) |
| DK (1) | DK2780326T3 (OSRAM) |
| EA (1) | EA026409B1 (OSRAM) |
| ES (1) | ES2713484T3 (OSRAM) |
| HU (1) | HUE041816T2 (OSRAM) |
| IL (1) | IL232118A (OSRAM) |
| MX (1) | MX345467B (OSRAM) |
| MY (1) | MY169330A (OSRAM) |
| PL (1) | PL2780326T3 (OSRAM) |
| PT (1) | PT2780326T (OSRAM) |
| SG (1) | SG11201401608PA (OSRAM) |
| WO (1) | WO2013058691A1 (OSRAM) |
| ZA (1) | ZA201403302B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102022575B1 (ko) * | 2011-10-19 | 2019-09-18 | 비보룩스 아베 | 탈유비퀴틴화 활성의 저해 방법 |
| JP2016504365A (ja) | 2012-12-28 | 2016-02-12 | アメリカ合衆国 | Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用 |
| WO2016004221A1 (en) * | 2014-07-01 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| MD3277677T2 (ro) * | 2015-03-30 | 2021-07-31 | Mission Therapeutics Ltd | Compuși de 1-ciano-pirolidină utilizați ca inhibitori de USP30 |
| CN106146542A (zh) * | 2015-04-23 | 2016-11-23 | 北京大学 | 姜黄素硼酸衍生物,其制备方法和应用 |
| GB201522768D0 (en) * | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| US10416163B2 (en) * | 2016-02-26 | 2019-09-17 | Regents Of The University Of Minnesota | Method and treatment of recurring endometrial cancer with an inhibitor of USP14 |
| JP2020506230A (ja) * | 2017-01-30 | 2020-02-27 | アップ セラピューティクス インコーポレイテッド | がん、糖尿病および神経障害の処置のための新規スピロおよび環式ビス−ベンジリジンプロテアソーム阻害剤 |
| CN111956804B (zh) * | 2020-07-21 | 2022-01-07 | 广州医科大学 | Otub1的抑制剂的新应用 |
| CN114959036A (zh) * | 2022-06-07 | 2022-08-30 | 北京大学 | Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU779230C (en) * | 1999-12-03 | 2006-05-25 | Emory University | Curcumin analogues for treating cancer |
| CA2478522A1 (en) * | 2002-03-08 | 2003-09-18 | Emory University | Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis |
| US20070010488A1 (en) * | 2005-04-13 | 2007-01-11 | Khairia Youssef | Compounds for modulating cell proliferation |
| EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| US7582655B2 (en) * | 2005-11-22 | 2009-09-01 | University Of Saskatchewan | Antineoplastic compounds |
| WO2011005790A1 (en) * | 2009-07-06 | 2011-01-13 | The Ohio State University Research Foundation | Compositions and methods for inhibition of cancers |
| KR102022575B1 (ko) * | 2011-10-19 | 2019-09-18 | 비보룩스 아베 | 탈유비퀴틴화 활성의 저해 방법 |
-
2012
- 2012-10-15 KR KR1020147012947A patent/KR102022575B1/ko not_active Expired - Fee Related
- 2012-10-15 BR BR112014009365-2A patent/BR112014009365B1/pt not_active IP Right Cessation
- 2012-10-15 WO PCT/SE2012/000158 patent/WO2013058691A1/en not_active Ceased
- 2012-10-15 PL PL12841677T patent/PL2780326T3/pl unknown
- 2012-10-15 CN CN201280062713.XA patent/CN104271557B/zh not_active Expired - Fee Related
- 2012-10-15 CA CA2852518A patent/CA2852518C/en active Active
- 2012-10-15 HU HUE12841677A patent/HUE041816T2/hu unknown
- 2012-10-15 PT PT12841677T patent/PT2780326T/pt unknown
- 2012-10-15 DK DK12841677.3T patent/DK2780326T3/en active
- 2012-10-15 AU AU2012326682A patent/AU2012326682B2/en not_active Ceased
- 2012-10-15 EP EP12841677.3A patent/EP2780326B1/en active Active
- 2012-10-15 JP JP2014537023A patent/JP6165748B2/ja not_active Expired - Fee Related
- 2012-10-15 MX MX2014004646A patent/MX345467B/es active IP Right Grant
- 2012-10-15 MY MYPI2014001125A patent/MY169330A/en unknown
- 2012-10-15 EA EA201490800A patent/EA026409B1/ru not_active IP Right Cessation
- 2012-10-15 SG SG11201401608PA patent/SG11201401608PA/en unknown
- 2012-10-15 ES ES12841677T patent/ES2713484T3/es active Active
-
2014
- 2014-04-13 IL IL232118A patent/IL232118A/en active IP Right Grant
- 2014-04-17 CL CL2014000998A patent/CL2014000998A1/es unknown
- 2014-04-18 US US14/256,280 patent/US9221761B2/en not_active Expired - Fee Related
- 2014-05-08 ZA ZA2014/03302A patent/ZA201403302B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6165748B2 (ja) | 脱ユビキチン活性の阻害方法 | |
| US20250120982A1 (en) | Covalent targeting of e3 ligases | |
| Zhang et al. | Targeting p53-MDM2-MDMX loop for cancer therapy | |
| D’Arcy et al. | Proteasome deubiquitinases as novel targets for cancer therapy | |
| Guédat et al. | Patented small molecule inhibitors in the ubiquitin proteasome system | |
| Liang et al. | Structure, functions and selective inhibitors of HDAC6 | |
| Vu et al. | Small-molecule inhibitors of the p53-MDM2 interaction | |
| JP2012031198A (ja) | 癌、炎症及び感染性疾患の治療のための、［３．２．０］複素環式化合物およびそれらの類縁体の使用 | |
| JP2000517319A (ja) | システインプロテアーゼのインヒビター | |
| Blaquiere et al. | Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases | |
| US9261497B2 (en) | Method of treating cancer with modulators of SCFSkp2 | |
| Clements et al. | Peptide deformylase inhibitors, potential for a new class of broad spectrum antibacterials | |
| US20130079370A1 (en) | Method for the Inhibition of Deubiquitinating Activity | |
| SE1200735A1 (sv) | Sätt att inhibera deubiqutineringsaktivitet | |
| JP2014526259A (ja) | プロテアソーム脱ユビキチン化阻害剤スクリーニング | |
| HK1203194B (en) | Method for inhibition of deubiquitinating activity | |
| NZ624019B2 (en) | Method for inhibition of deubiquitinating activity | |
| Zhenodarova | Small-molecule caspase inhibitors | |
| Chan | Conversion of Small-Molecule Inhibitors to Heterobifunctional Compounds Towards the Development of Novel Chemotherapeutics | |
| Chan | Conversion of Small-Molecule Inhibitors into Heterobifunctional Compounds in the Discovery of Novel Chemotherapeutics | |
| Ciceri et al. | Biocatalytic synthesis of two pharmacologically active compounds:(S)-pramipexole and its enantiomer, dexpramipexole. | |
| Mao et al. | The ubiquitin-proteasomal system and blood cancer therapy | |
| Dang | NF‐κB Mechanism, Tumor Biology, and Inhibitors | |
| Lindamulage | Characterisation of CTR-17 and CTR-20, novel chalcone derivatives that inhibit tubulin polymerisation activity | |
| HK1175115A (en) | Treatment of protein degradation disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151001 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151008 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160527 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160526 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20160630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160822 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161011 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20161122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170228 |
|
| RD14 | Notification of resignation of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7434 Effective date: 20170309 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170525 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170616 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170621 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6165748 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |